On the enhancement of anti-neurotoxin antibody production by subcomponents HA1 and HA3b of Clostridium botulinum type B 16S toxin-haemagglutinin

References

1. Aoki K. R. 2002; Immunologic and other properties of therapeutic botulinum toxin serotypes. In Scientific and Therapeutic Aspects of Botulinum Toxin pp  103–113 Edited by Brin M. F., Hallett M., Jankovic J. Philadelphia: Lippincott Williams & Wilkins;
   [Google Scholar]
2. Arimitsu H, Inoue K, Sakaguchi Y, Lee J, Fujinaga Y, Watanabe T, Ohyama T, Hirst R, Oguma K. 2003; Purification of fully activated Clostridium botulinum serotype B toxin for treatment of patients with dystonia. Infect Immun 71:1599–1603 [CrossRef]
   [Google Scholar]
3. Atassi M. Z. 1977; Chemical modification and cleavage of proteins and chemical strategy in immunochemical studies of proteins. In Immunochemistry of Proteins vol. 1 pp  1–161 Edited by Atassi M. Z. New York: Plenum;
   [Google Scholar]
4. Atassi M. Z. 1984; Antigenic structures of proteins. Their determination has revealed important aspects of immune recognition and generated strategies for synthetic mimicking of protein binding sites. Eur J Biochem 145:1–20 [CrossRef]
   [Google Scholar]
5. Atassi M. Z. 2002; Immune recognition and cross-reactivity of botulinum neurotoxins. In Scientific and Therapeutic Aspects of Botulinum Toxins pp  385–408 Edited by Brin M. F., Hallett M., Jankovic J. Philadelphia: Lippincott Williams & Wilkins;
   [Google Scholar]
6. Atassi M. Z. 2004; Basic immunological aspects of botulinum toxin therapy. Mov Disord Suppl 8:S68–S84
   [Google Scholar]
7. Atassi M. Z, Oshima M. 1999; Structure, activity, and immune (T and B cell) recognition of botulinum neurotoxins. Crit Rev Immunol 19:219–260
   [Google Scholar]
8. Atassi M. Z, Dolimbek B. Z, Hayakari M, Middlebrook J. L, Whitney B, Oshima M. 1996; Mapping of the antibody-binding regions on botulinum neurotoxin H-Chain domain 855–1296 with anti-toxin antibodies from three host species. J Protein Chem 15:691–700 [CrossRef]
   [Google Scholar]
9. Atassi M. Z, Dolimbek G. S, Deitiker P. R, Aoki K. R, Dolimbek B. Z. 2005; Submolecular recognition profiles in two mouse strains of non-protective and protective antibodies against botulinum neurotoxin A. Mol Immunol 42:1509–1520 [CrossRef]
   [Google Scholar]
10. Borodic G. E, Acquadro M, Johnson E. A. 2001; Botulinum toxin therapy for pain and inflammatory disorders: mechanisms and therapeutic effects. Expert Opin Investig Drugs 10:1531–1544 [CrossRef]
    [Google Scholar]
11. Brashear A, Lew M. F, Dykstra D. D. 10 other authors 1999; Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 53:1439–1446 [CrossRef]
    [Google Scholar]
12. Brashear A, McAfee A. L, Kuhn E. R, Fyffe J. 2004; Botulinum toxin type B in upper-limb poststroke spasticity: a double-blind, placebo-controlled trial. Arch Phys Med Rehabil 85:705–709 [CrossRef]
    [Google Scholar]
13. Callaway J. E, Arezzo J. C, Grethlein A. J. 2002; Botulinum toxin type B: an overview of its biochemistry and preclinical pharmacology. Dis Mon 48:367–383 [CrossRef]
    [Google Scholar]
14. Chen J, Fitos I, Hage D. S. 2006; Chromatographic analysis of allosteric effects between ibuprofen and benzodiazepines on human serum albumin. Chirality 18:24–36 [CrossRef]
    [Google Scholar]
15. Coyle E. M, Blazer L. L, White A. A, Hess J. L, Boyle M. D. 2006; Practical applications of high-affinity, albumin-binding proteins from a group G streptococcal isolate. Appl Microbiol Biotechnol 71:39–45 [CrossRef]
    [Google Scholar]
16. Dolimbek G. S, Dolimbek B. Z, Aoki K. R, Atassi M. Z. 2005; Mapping of the antibody and T cell recognition profiles of the H[sub]N[/sub] domain (residues 449–859) of the heavy chain of botulinum neurotoxin A in two high-responder mouse strains. Immunol Invest 34:119–142
    [Google Scholar]
17. Dressler D, Bigalke H. 2005; Botulinum toxin type B de novo therapy of cervical dystonia frequency of antibody induced therapy failure. J Neurol 252:904–907 [CrossRef]
    [Google Scholar]
18. Göschel H, Wohlfarth K, Frevert J, Dengler R, Bigalke H. 1997; Botulinum A toxin therapy: neutralizing and nonneutralizing Abs – therapeutic consequences. Exp Neurol 147:96–102 [CrossRef]
    [Google Scholar]
19. Inagi K, Ford C. N, Rodriquez A. A, Schultz E, Bless D. M, Heisey D. M. 1997; Efficacy of repeated botulinum toxin injections as a function of timing. Ann Otol Rhinol Laryngol 106:1012–1019 [CrossRef]
    [Google Scholar]
20. Jankovic J. 2002; Botulinum toxin clinical implications of antigenicity and immunoresistance. In Scientific and Therapeutic Aspects of Botulinum Toxin pp  409–415 Edited by Brin M. F., Hallett M., Jankovic J. Philadelphia: Lippincott Williams & Wilkins;
    [Google Scholar]
21. Jankovic J. 2004; Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatr 75:951–957 [CrossRef]
    [Google Scholar]
22. Jankovic J, Hunter C, Atassi M. Z, Dolimbek B. Z, Dolimbek G. S. BOS Research Group 2005; Botulinum toxin type B observational study (BOS). Mov Disord 20:S31
    [Google Scholar]
23. Jemmerson R, Margoliash E. 1978 In Immunobiology of Proteins and Peptides vol. 1 pp  119–129 Edited by Atassi M. Z., Stavitsky A. B. New York: Plenum;
    [Google Scholar]
24. Jemmerson R, Margoliash E. 1979; Topographic antigenic determinants on cytochrome c . Immunoadsorbent separation of the rabbit antibody populations directed against horse cytochrome. J Biol Chem 254:12706–12716
    [Google Scholar]
25. Komatsu T, Ohmichi N, Nakagawa A, Zunszain P. A, Curry S, Tsuchida E. 2005; O[sub]2[/sub] and CO binding properties of artificial hemoproteins formed by complexing iron protoporphyrin IX with human serum albumin mutants. J Am Chem Soc 127:15933–15942 [CrossRef]
    [Google Scholar]
26. Lee J.-C, Yokota K, Arimitsu H. 7 other authors 2005; Production of anti-neurotoxin antibody is enhanced by two subcomponents, HA1 and HA3b, of Clostridium botulinum type B 16S toxin-haemagglutinin. Microbiology 151:3739–3747 [CrossRef]
    [Google Scholar]
27. Lin H. C, Chen P. C, Cheng T. J, Chen R. L. 2004; Formation of tannin-albumin nano-particles at neutral pH as measured by light scattering techniques. Anal Biochem 325:117–120 [CrossRef]
    [Google Scholar]
28. Marini I, Moschini R, Corso A. D, Mura U. 2005; Chaperone-like features of bovine serum albumin: a comparison with alpha-crystallin. Cell Mol Life Sci 62:3092–3099 [CrossRef]
    [Google Scholar]
29. Means G. E, Feeney R. E. 1971 Chemical Modification of Proteins San Francisco: Holden-Day;
    [Google Scholar]
30. Militello V, Casarino C, Emanuele A, Giostra A, Pullara F, Leone M. 2004; Aggregation kinetics of bovine serum albumin studied by FTIR spectroscopy and light scattering. Biophys Chem 107:175–187 [CrossRef]
    [Google Scholar]
31. Oliva A, Santovena A, Farina J, Llabres M. 2003; Effect of high shear rate on stability of proteins: kinetic study. J Pharm Biomed Anal 33:145–155 [CrossRef]
    [Google Scholar]
32. Poewe W, Deuschl G, Nebe A. 8 other authors 1998; What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group. J Neurol Neurosurg Psychiatr 64:13–17 [CrossRef]
    [Google Scholar]
33. Reichlin M, Nisonoff A, Margoliash E. 1970; Immunological activity of cytochrome c . 3. Enhancement of antibody detection and immune response initiation by cytochrome c polymers. J Biol Chem 245:947–954
    [Google Scholar]
34. Rosenberg J. S, Middlebrook J. L, Atassi M. Z. 1997; Localization of the regions on the C-terminal domain of the heavy chain of botulinum toxin A recognized by T-lymphocytes and by antibodies after immunization of mice with pentavalent toxoid. Immunol Invest 26:491–504 [CrossRef]
    [Google Scholar]
35. Rozak D. A, Orban J, Bryan P. N. 2005; G148-GA3: a streptococcal virulence module with atypical thermodynamics of folding optimally binds human serum albumin at physiological temperatures. Biochim Biophys Acta 1753226–233 [CrossRef]
    [Google Scholar]
36. Vaiana S. M, Emanuele A, Palma-Vittorelli M. B, Palma M. U. 2004; Irreversible formation of intermediate BSA oligomers requires and induces conformational changes. Proteins 55:1053–1062 [CrossRef]
    [Google Scholar]
37. Yablon S. A, Daggett S, Brin M. F. 2005 Toxin neutralizing antibody formation with botulinum toxin type A (BoNTA) treatment. In 57th Annual Meeting of the American Academy of Neurology , Abstract P01.153, 12 April 2005 Miami Beach, Florida:
    [Google Scholar]
38. Young C. R, Atassi M. Z. 1982; Genetic control of the immune response to myoglobin. IX. Overcoming genetic control of antibody response to antigenic sites by increasing the dose of antigen used in immunization. J Immunogen 9:343–351 [CrossRef]
    [Google Scholar]